Acute gastroduodenal mucosal injury after cisplatin plus etoposide chemotherapy. Clinical and endoscopic study.

abstract：OBJECTIVES:A novel delivery system for transdermal matrix patches of fentanyl has been developed. The new fentanyl tape consists of a backing layer, a drug-containing layer and a release liner that is originally made of rubber adhesive. This open-label prospective study investigated the pharmacokinetics and safety of t...

journal_title：Oncology

authors： Saito T,Fujii M,Saito S,Shimada K,Fujiwara K,Kobayashi K

更新日期：2014-01-01 00:00:00

abstract：:Little is known about the expression and antioxidant function of manganese superoxide dismutase (Mn-SOD) in esophageal squamous cell carcinoma. To determine the significance of Mn-SOD in esophageal squamous cell carcinomas, Mn-SOD mRNA expression was examined in 45 esophageal squamous cell carcinomas and the correspon...

journal_title：Oncology

authors： Toh Y,Kuninaka S,Mori M,Oshiro T,Ikeda Y,Nakashima H,Baba H,Kohnoe S,Okamura T,Sugimachi K

更新日期：2000-09-01 00:00:00

abstract：OBJECTIVES:Primary chemoradiotherapy for locally advanced pancreatic cancer (LAPC) may improve local control, curative resection rate and long-term survival. We performed a phase II study to evaluate toxicity and activity of primary radiation therapy and concurrent chemotherapy with gemcitabine (GEM) twice weekly in pa...

journal_title：Oncology

authors： Magnino A,Gatti M,Massucco P,Sperti E,Faggiuolo R,Regge D,Capussotti L,Gabriele P,Aglietta M

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:Transarterial chemoembolization (TACE) is recommended as a first-line therapy for hepatocellular carcinoma (HCC) patients ineligible for curative therapy and without portal invasion. The Assessment for Retreatment with TACE (ART) scoring system was recently proposed for identifying patients who would not show...

journal_title：Oncology

authors： Arizumi T,Ueshima K,Iwanishi M,Minami T,Chishina H,Kono M,Takita M,Kitai S,Inoue T,Yada N,Hagiwara S,Ida H,Minami Y,Sakurai T,Nishida N,Kitano M,Kudo M

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:An increasing number of patients with advanced pancreatic or biliary tract cancer who progress after a gemcitabine-containing regimen are candidates for further chemotherapy. We therefore evaluated a fully oral regimen of capecitabine and celecoxib (CapCel) as second-line treatment in these patients. METHODS...

journal_title：Oncology

authors： Pino MS,Milella M,Gelibter A,Sperduti I,De Marco S,Nuzzo C,Bria E,Carpanese L,Ruggeri EM,Carlini P,Cognetti F

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy. While cisplatin, anthracyclines and ifosfamide are the most commonly used agents in the treatment of osteosarcoma, a search for the best combination with higher efficacy and minimal toxicity continues. We pl...

journal_title：Oncology

authors： Basaran M,Bavbek ES,Saglam S,Eralp L,Sakar B,Atalar AC,Bilgic B,Ozger H,Onat H

更新日期：2007-01-01 00:00:00

abstract：INTRODUCTION:Breast cancer is one of the leading causes of death worldwide and is the result of dysregulation of various signaling pathways in mammary epithelial cells. The mortality rate in patients suffering from breast cancer is high because the tumor cells have a prominent invasive capacity towards the surrounding ...

journal_title：Oncology

authors： González-González L,González-Ramírez R,Flores A,Avelino-Cruz JE,Felix R,Monjaraz E

更新日期：2019-01-01 00:00:00

abstract：:The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this setting, prompted us to investigate the effectiveness of a carboplatin-containing regimen in a p...

journal_title：Oncology

authors： Briasoulis E,Tsavaris N,Fountzilas G,Athanasiadis A,Kosmidis P,Bafaloukos D,Skarlos D,Samantas E,Pavlidis N

更新日期：1998-09-01 00:00:00

abstract：:Three polycyclic hydrocarbons: benzo(a)pyrene; dibenz(a,h)-anthracene and dibenz(a,c)anthracene, differing in their carcinogenicity, were administered to female rats. The comparative intracellular localization of these compounds was studied by fluorescence microscopy. The two carcinogenic molecules were localized both...

journal_title：Oncology

authors： Stora C

更新日期：1980-01-01 00:00:00

abstract：OBJECTIVES:Anaplastic oligodendrogliomas (AO) are uncommon primary brain tumors whose natural history, prognosis, and optimal management are not yet fully understood. However, they are associated with a better prognosis and response to multimodality therapy based on specific molecular changes. In this multicenter retro...

journal_title：Oncology

authors： Puduvalli VK,Hashmi M,McAllister LD,Levin VA,Hess KR,Prados M,Jaeckle KA,Yung WK,Buys SS,Bruner JM,Townsend JJ,Davis R,Sawaya R,Kyritsis AP

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Mutations in the human telomerase reverse transcriptase (hTERT) gene promoter have been reported in hepatocellular carcinoma (HCC); however, analyses of these mutations in liquid biopsies have been technically difficult because of the high GC content of the regions of interest within this promoter. We evalua...

journal_title：Oncology

authors： Ako S,Nouso K,Kinugasa H,Matsushita H,Terasawa H,Adachi T,Wada N,Takeuchi Y,Mandai M,Onishi H,Ikeda F,Shiraha H,Takaki A,Fujioka S,Mimura T,Okada H

更新日期：2020-01-01 00:00:00

abstract：OBJECTIVES:Systematic investigation of a novel series of intercalating agents, 9-aza-anthrapyrazoles, has led to the identification of a promising analogue, BBR 3438. This study describes the antitumour efficacy of the novel compound in human prostate carcinoma models and the molecular/cellular basis of its activity. ...

journal_title：Oncology

authors： Supino R,Polizzi D,Pavesi R,Pratesi G,Guano F,Capranico G,Palumbo M,Sissi C,Richter S,Beggiolin G,Menta E,Pezzoni G,Spinelli S,Torriani D,Carenini N,Dal Bo L,Facchinetti F,Tortoreto M,Zunino F

更新日期：2001-01-01 00:00:00

abstract：PURPOSE:To determine the dose-limiting toxicities (DLTs) and the maximum-tolerated doses of the paclitaxel, oxaliplatin (LOHP) and capecitabine combination in patients with advanced solid tumors. PATIENTS AND METHODS:Patients received escalating doses of paclitaxel (starting dose 100 mg/m2) and LOHP (starting dose 40 ...

journal_title：Oncology

authors： Saridaki Z,Bozionelou V,Kentepozidis N,Kotsakis A,Vardakis N,Kalykaki A,Gioulbasanis I,Karampeazis A,Vamvakas L,Georgoulias V,Mavroudis D

更新日期：2007-01-01 00:00:00

abstract：:Magnetic resonance imaging-guided laser interstitial thermal therapy (LITT) is a minimally invasive treatment modality with recent increasing use to ablate brain tumors. When originally introduced in the late 1980s, the inability to precisely monitor and control the thermal ablation limited the adoption of LITT in neu...

journal_title：Oncology

authors： Rahmathulla G,Recinos PF,Kamian K,Mohammadi AM,Ahluwalia MS,Barnett GH

更新日期：2014-01-01 00:00:00

abstract：:There are numerous data on the immunostimulative and antitumorous activity of various Viscum album tissue extracts. Isorel (Novipharm, Austria) is one of these compounds. We found that in mice an increased number of plaque-forming cells to sheep red blood cells (SRBC) followed the injection of Isorel together with SRB...

journal_title：Oncology

authors： Jurin M,Zarković N,Hrzenjak M,Ilić Z

更新日期：1993-11-01 00:00:00

abstract：:Abundant expression of thymidine phosphorylase (TP) mRNA and protein was observed in human carcinoma tissues relative to the corresponding normal tissues. However, the distribution of cells that express TP has not yet been determined. In this study, we examined enzyme activity of TP in 24 primary colorectal carcinoma ...

journal_title：Oncology

authors： Mimori K,Matsuyama A,Yoshinaga K,Yamashita K,Masuda T,Inoue H,Ueo H,Mori M

更新日期：2002-01-01 00:00:00

abstract：:The effects of the gamma-amino-n-butyric acid (GABA)A receptor agonist muscimol, and the GABAB receptor agonist baclofen, on colon carcinogenesis induced by azoxymethane in Wistar rats were tested. Administration of either muscimol or baclofen had no influence on the incidence of colon tumors at week 30. However, almo...

journal_title：Oncology

authors： Tatsuta M,Iishi H,Baba M,Taniguchi H

更新日期：1992-01-01 00:00:00

abstract：:The methodology of future antiemetic studies will reflect the need to address the problems identified in current studies. New preclinical information on the mechanisms of emesis and antiemetic action will allow more rational clinical study design. Prior to large randomized studies, phase I and II trials should define ...

journal_title：Oncology

authors： Olver IN

更新日期：1996-06-01 00:00:00

abstract：PURPOSE:To evaluate the efficacy and safety of neoadjuvant treatment comprising weekly high-dose 5-fluorouracil (5-FU) as a 24-hour infusion, folinic acid (FA) and biweekly oxaliplatin (L-OHP), followed by metastatic resection in patients with primarily resectable liver metastases of colorectal cancer (CRC). PATIENTS ...

journal_title：Oncology

authors： Wein A,Riedel C,Brückl W,Merkel S,Ott R,Hanke B,Baum U,Fuchs F,Günther K,Reck T,Papadopoulos T,Hahn EG,Hohenberger W

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVE:Ovarian cancer is the most lethal gynecological malignancy, but information relevant to prognosis and outcomes remain unknown. Here, we used statistical methods to focus specifically on interactions between candidate prognostic variables. METHODS AND RESULTS:Univariate, multivariate, and elastic net modeling...

journal_title：Oncology

authors： Jatoi A,Vierkant RA,Hawthorne KM,Block MS,Ramus SJ,Larson NB,Fridley BL,Goode EL

更新日期：2016-01-01 00:00:00

abstract：:We evaluated changes in serum albumin concentrations in 15 patients with advanced malignancy who were also receiving cisplatin. All 15 patients had serial measurements of serum albumin. The decrease in serum albumin from the time of the first dose of cisplatin to death correlated with liver platinum levels at autopsy ...

journal_title：Oncology

authors： Nanji AA,Mikhael NZ,Stewart DJ

更新日期：1986-01-01 00:00:00

abstract：:The levels of bone-specific alkaline phosphatase (BALP) in plasma and tumour tissue samples of 20 Chinese patients with osteosarcoma in Hong Kong were measured by the wheat germ lectin precipitation technique. The plasma BALP levels in these patients were significantly higher than those of the normal subjects (p < 0.0...

journal_title：Oncology

authors： Liu PP,Leung KS,Kumta SM,Lee KM,Fung KP

更新日期：1996-07-01 00:00:00

abstract：BACKGROUNDS AND AIMS:Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) is a phospholipid mediator and acts by binding to a specific G-protein-coupled receptor. Though various functions of PAF have been associated with tumor activities, the mechanism of PAF-PAF receptor signaling in the de...

journal_title：Oncology

authors： Kitagawa D,Taketomi A,Kayashima H,Kuroda Y,Itoh S,Yamashita Y,Maehara Y

更新日期：2007-01-01 00:00:00

abstract：:Inhibitors of polyamine synthesis were tested for therapeutic effectiveness on transplantable prostate cancer. Inhibition of either ornithine decarboxylase or S-adenosyl-L-methionine decarboxylase (AMDC) by alpha-difluormethylornithine (DFMO) or methylglyoxal-bis[guanylhydrazone] (MGBG), respectively, was associated w...

journal_title：Oncology

authors： Dunzendorfer U,Relyea NM,Kleinert E,Balis ME,Whitmore WF Jr

更新日期：1983-01-01 00:00:00

abstract：OBJECTIVE:The pretreatment neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have been reported to be useful as markers for prognostic factors and metastasis in several cancers. The aim of this study was to identify the predictor of lymph node (LN) metastasis by pretreatment NLR and PLR in...

journal_title：Oncology

authors： Aoyama T,Takano M,Miyamoto M,Yoshikawa T,Kato K,Sakamoto T,Takasaki K,Matsuura H,Soyama H,Hirata J,Suzuki A,Sasa H,Tsuda H,Furuya K

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Neoadjuvant chemotherapy (NAC) has become prevalent in esophageal squamous cell carcinoma (ESCC), but its long-term prognostic advantages remain unclear. The latest prognostic outcomes in clinical Stage (cStage) II/III ESCC with NAC were herein elucidated. PATIENTS AND METHODS:NAC prior to curative treatmen...

journal_title：Oncology

authors： Yamashita K,Hosoda K,Moriya H,Katada C,Sugawara M,Mieno H,Komori S,Katada N,Watanabe M

更新日期：2017-01-01 00:00:00

abstract：OBJECTIVES:It was the aim of this study to evaluate clinicopathological characteristics and prognostic factors of uterine leiomyosarcomas (LMS). METHODS:Twenty-eight patients with uterine LMS were evaluated in this retrospective study. Their features and survival were analyzed by Kaplan-Meier and log-rank tests. RESU...

journal_title：Oncology

authors： Loizzi V,Cormio G,Nestola D,Falagario M,Surgo A,Camporeale A,Putignano G,Selvaggi L

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:The tumor suppressor gene p53 is a nuclear protein which plays a key role in tumor progression by regulating DNA repair, cell division and apoptosis. One major function of wild-type p53 is to control the onset of DNA replication at the G1-S boundary by inducing p21 protein, which promotes cell cycle arrest b...

journal_title：Oncology

authors： Okuyama T,Maehara Y,Kabashima A,Takahashi I,Kakeji Y,Sugimachi K

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND AND AIM:In vitro, methotrexate (MTX) is the best modulator for bolus 5-fluorouracil (5FU), whereas folinic acid (FA) is the best for continuous infusion. We evaluated the effect of 5FU modulated by both MTX (bolus administration) and FA (continuous infusion) as second-line treatment of patients with metastat...

journal_title：Oncology

authors： Carlomagno C,Lauria R,De Laurentiis M,Arpino G,Massarelli E,Ferrara C,Milano A,Vernaglia Lombardi A,Costanzo R,Catalano G,Bianco AR,De Placido S

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:The aim of this study was to investigate the outcomes of gemcitabine-treated patients with inoperable biliary tract cancers. METHODS:We conducted a retrospective study of consecutively treated 22 inoperable biliary tract cancer patients with gemcitabine (500-1,000 mg/m(2) on days 1, 8, 15 every 4 weeks) as f...

journal_title：Oncology

authors： Kiba T,Nishimura T,Matsumoto S,Hatano E,Mori A,Yasumi S,Doi R,Ikai I,Kitano T,Nishimura T,Yoshikawa K,Ishiguro H,Yanagihara K,Doi E,Teramukai S,Fukushima M

更新日期：2006-01-01 00:00:00